Puma raises 2025 guidance; Q3 GAAP net income $8.8M vs $20.3M YoY on lower royalty revenue

PUMA BIOTECHNOLOGY, INC.

2025-Q3 EPS reported $0.35 revenue$152,918,000

Q3 GAAP net income $8.8M ($0.17 diluted) vs $20.3M ($0.41) YoY; non-GAAP adj. net income $10.5M ($0.21) vs $22.4M ($0.46).
Q3 product revenue $51.9M (vs $56.1M); total revenue $54.5M (vs $80.5M) driven by lower royalty from China licensee.
Updated FY2025 guidance: product revenue $198-200M, total revenue $220-223M, net income $27-29M (all raised from prior).
Cash & securities $94.4M at Sep 30, 2025; operating cash flow $9.7M in Q3.
Interim data from ALISCA-Breast1 and ALISCA-Lung1 alisertib trials expected H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.